Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Tokyo Big Sight

Nov 13, 2016 9:30 AM - Nov 15, 2016 5:30 PM

3-11-1 Ariake, Koto-ku, Tokyo, 135-0063 Japan

13th DIA Japan Annual Meeting 2016

Keynote Address 1

Session Chair(s)

Yoshinobu  Hirayama, PhD

Yoshinobu Hirayama, PhD

Professor, College of Pharmaceutical Sciences

Ritsumeikan University, Japan

iPS cells have dramatically shortened the distance from research to patients, and made it possible for patients to get involved in medicinal development. Research has been conducted to establish iPS cells from patients with various genetic diseases, promote scientific analysis of pathological disease conditions with known genetic etiology at the cell level, and determine a variety of factors which affect pathological conditions by analyzing somatic cells from patients with unknown genetic etiology. In addition, iPS cells are used to verify the safety of medicine as well as search for candidates for new medicine. Furthermore, they enable cell transplant therapy by combination with gene therapy. In this session, Dr. Nakahata will introduce the current situation and future possibilities of new medicine development brought by iPS cells.

Speaker(s)

Tatsutoshi  Nakahata, MD, PhD

Recent Progress in iPS Cell Research and Application

Tatsutoshi Nakahata, MD, PhD

Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan

Deputy Director and Professor

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.